Why a torn ACL needs a tendon graft

A complete tear of the anterior cruciate ligament presents a particular surgical challenge: unlike many soft-tissue injuries, the ACL cannot be stitched back together and left to heal. The ligament's poor intrinsic blood supply means that suture repair alone fails, and the joint remains unstable. Reconstruction — replacing the torn ligament with a tendon graft that gradually integrates into the knee — is therefore the standard surgical route for patients who want to return to sport or physically demanding activity.

Three sources of graft tissue dominate current practice. The bone-patellar tendon-bone (BPTB) graft, taken from the front of the knee, has the longest track record. Hamstring tendon (HT) autograft, using the semitendinosus and sometimes the gracilis, has been widely adopted for its smaller scar and gentler early recovery. Quadriceps tendon (QT) autograft, harvested from the thigh just above the kneecap, is the most rapidly growing option among high-volume ACL surgeons. A fourth possibility — allograft, sourced from cadaveric donor tissue — is used in specific circumstances, but published data suggest it carries roughly three times the re-tear risk of autograft in young, active patients, limiting its role to older or lower-demand individuals.

For most patients, the central question is which autograft to choose. A 2019 systematic review by Mouarbes et al., cited more than 580 times in the surgical literature, concluded that no single option is universally superior. Outcomes are shaped more by surgical precision, rehabilitation adherence, and careful patient selection than by the graft material itself. What this means in practice is that the right graft for one patient may not be the right graft for another. The sections below map the trade-offs — re-tear risk, donor-site morbidity, return-to-sport data, and recovery profile — so that the decision can be properly tailored in conversation with a surgeon.

Patellar tendon (BPTB): the historical benchmark

Bone-to-bone healing is the defining biological advantage of the BPTB graft. The patellar tendon is harvested with a small plug of bone at each end; these plugs sit inside the femoral and tibial tunnels and fuse directly with the surrounding bone, producing biological fixation that is faster and more mechanically secure in the early post-operative weeks than the soft-tissue integration required by the other two autograft options. Long-term re-tear rates are consistently among the lowest recorded for any autograft, and the technique carries decades of published follow-up to support that track record.

The trade-off is concentrated at the donor site. Anterior knee pain, numbness across the front of the kneecap, and discomfort when kneeling are reported at higher rates with BPTB than with hamstring or quadriceps tendon grafts. For many patients these symptoms are manageable and resolve over time, but for those who kneel repeatedly — in trades such as flooring, tiling, or plumbing, or for religious practice — the burden can be disproportionate and persistent. A prior history of patellar tendinopathy is a relative contraindication to BPTB harvest, since removing part of an already-stressed tendon increases the risk of further donor-site problems.

Real-world sentiment data offer a corroborating signal: a 2025 social media analysis by Thiru et al. found that 18.9% of posts about BPTB were negative, compared with 8.9% for quadriceps tendon, with donor-site complaints as the dominant theme. This does not make BPTB the wrong choice — for a patient without kneeling demands and no tendinopathy history, its stability record remains genuinely compelling.

Hamstring tendon: the early-recovery favourite with a re-tear caveat

The hamstring tendon graft's most immediate advantage is felt in the first fortnight after surgery. Harvest involves a small incision behind the knee with no bone removal, so patients typically experience less anterior knee pain and can kneel more comfortably than those recovering from a BPTB procedure — often translating into a lower analgesic burden and an easier start to rehabilitation.

The biomechanical picture is more nuanced over time. Hamstring grafts rely on soft-tissue integration within the bone tunnels, a process that is inherently slower than bone-to-bone healing. This has practical implications for load progression during early rehabilitation, and it is one reason that graft laxity features in comparative outcome data. On re-rupture risk, the 2022 Hurley meta-analysis found that hamstring tendon autograft carries a statistically higher re-rupture rate than quadriceps tendon autograft — a gap that becomes stark in revision cases, where published failure rates of 17.4% for hamstring tendon contrast with 2.3% for quadriceps tendon. Persistent hamstring strength deficits following harvest are also documented; athletes whose sport demands repeated powerful hamstring contractions — sprinting, football, or rugby — require targeted strengthening to address this specific weakness as part of their rehabilitation programme.

Where hamstring tendon remains a well-supported option is for a patient in their forties or older returning to recreational, low-pivot activity — cycling, swimming, or brisk walking — who places a high priority on minimising early post-operative morbidity and has no hamstring-dependent sport to return to. For that profile, the graft's comfort advantages are genuine and its biomechanical limitations are considerably less consequential.

Quadriceps tendon: the growing choice for demanding athletes

Adoption of the quadriceps tendon graft has grown markedly among high-volume ACL surgeons over the past decade, and the structural rationale is straightforward. Harvested from the central third of the quadriceps tendon above the patella, the graft contains approximately 20% more collagen fibrils per cross-sectional area than patellar tendon — a difference that translates into superior load-to-failure strength before any biological integration has taken place.

The outcome data reflect that structural advantage. Hurley et al.'s 2022 meta-analysis confirmed a statistically lower re-rupture rate for quadriceps tendon versus hamstring tendon autograft — a finding that has shifted graft preference particularly for younger, higher-demand patients where a re-tear carries the greatest long-term consequence. Return-to-sport figures add to the picture: a 2024 study by Dadoo et al. followed 89 adolescent athletes (mean age 16.2 years) for a mean of four years after QT ACL reconstruction and recorded 80% return to sport at a mean of 9.7 months, with 85% reaching or exceeding their pre-injury sport level and IKDC scores improving from 37.5 before surgery to 88.5 afterwards. These results come from a motivated cohort, and comparative data beyond 10 years are thinner for QT than for either BPTB or hamstring tendon — a gap the literature has not yet closed.

Two recovery-specific issues deserve transparent discussion. Harvest from the quadriceps mechanism causes pain-mediated muscle inhibition in the first one to two months after surgery — a rehabilitation challenge rather than a lasting deficit, but one that requires targeted strengthening and should not be underestimated in programme planning. The donor site itself regenerates functionally within approximately 6–12 months. Separately, QT harvest is technically more demanding than BPTB or hamstring tendon procedures, which means surgeon experience and operative volume are relevant considerations when deciding where to have the operation performed.

Five factors that personalise your graft decision

No two ACL patients arrive at the surgical conversation with the same profile. These five factors are the ones that most reliably shift the evidence in one direction or another — and most patients will find themselves balancing at least two or three of them simultaneously.

Re-tear risk tolerance and sport intensity. If you play high-pivot sport — football, netball, skiing — or simply cannot afford the disruption of a second reconstruction, re-rupture risk is the dominant consideration. Both BPTB and quadriceps tendon autograft outperform hamstring tendon on this measure across the published meta-analyses, and in a revision setting the gap is particularly striking. High-demand athletes and those with a strong return-to-sport ambition therefore tend to be steered toward QT or BPTB as a starting point.

Kneeling demands. If your work, faith practice, or daily routine involves prolonged or repeated kneeling, the BPTB donor site creates a sustained practical problem. Hamstring tendon and quadriceps tendon grafts both carry considerably lower rates of kneeling discomfort, making either a more comfortable long-term fit for this group.

Early versus late recovery priority. Hamstring tendon typically offers the gentlest first few weeks. Quadriceps tendon and BPTB carry stronger long-term stability data — though this comes with a more demanding initial rehabilitation phase, particularly regarding quadriceps inhibition after QT harvest.

Pre-existing tendinopathy. A history of patellar tendinopathy is a relative contraindication to harvesting the patellar tendon; similarly, chronic quadriceps tendinopathy may influence whether QT harvest is advisable. Declaring any previous tendon trouble to your surgeon before the decision is made matters.

Surgeon experience and volume. QT harvest is technically more demanding than either of the alternatives, and outcomes across all three graft types are closely tied to surgical precision. The experience and annual volume a surgeon has with a given technique is a legitimate — and often underweighted — factor when choosing where to have the operation.

In practice, most patients have a mix of these considerations, and some factors will pull in opposite directions. The surgeon consultation is the point at which they are weighed together against your specific anatomy, imaging findings, and goals — not resolved by any single article.

What rehabilitation looks like after each graft

Regardless of which autograft is chosen, most patients target the same broad milestone: return to unrestricted sport at around nine to twelve months. What differs is where the rehabilitation emphasis falls in the weeks immediately after surgery.

After a BPTB reconstruction, early patellar mobilisation is a priority — the harvest site can tighten the soft tissue around the kneecap, and patellar mobility work in the first few weeks protects longer-term function. Kneeling discomfort often outlasts the sport return milestone and should be factored into the rehab plan rather than treated as a problem resolved once the graft is healed.

Hamstring tendon patients tend to find the early weeks easier, but the middle and later phases demand more than they initially appear. Hamstring strength deficits can persist well past the point of feeling recovered, and easing off the targeted strengthening once basic functional milestones are reached is a pattern that can compromise long-term graft stability. That work does not stop at six months.

With a quadriceps tendon graft, the first six to eight weeks centre on reactivating the quadriceps mechanism. Harvest pain triggers temporary muscle inhibition — a normal physiological response, not a surgical complication — and progressive loading to overcome it is the central early task. Once that phase is navigated, the rehabilitation arc broadly mirrors the other two autografts.

The Dadoo 2024 cohort study offers a useful illustration across graft types: among adolescent athletes who had not returned to sport by follow-up, the most commonly reported barriers were lack of time (70%) and fear of reinjury (50%) — neither a clinical finding, both addressable with structured support. Across the evidence base, programme adherence and psychological readiness at the point of return-to-sport testing predict final outcomes more reliably than graft material alone.